Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Natera, Inc. (NASDAQ: NTRA) (“Natera” or the “Company”), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focus on investors’ losses and whether they may be recovered under the federal securities laws.
What if I purchased Natera common stock? If you purchased Natera common stock and suffered significant losses on your investment, join our investigation now:
Click [here] or paste the following web address into your browser to submit your losses: https://www.cognitoforms.com/JohnsonFistel/NateraInc2
Or for more information, contact Jim Baker at [email protected] or (619) 814-4471
There is no cost or obligation to you.
What is Johnson Fistel investigating? On January 1, 2022, New York Times released an article regarding the efficacy of Natera’s tests for DiGeorge syndrome. The report states, “The analysis showed that positive results on those tests are incorrect about 85 percent of the time.”
Then, on January 14, 2022, the Campaign for Accountability (“CfA”) filed a complaint letter with the Securities and Exchange Commission (“SEC”), alleging that Natera misled investors by, among other things, failing to disclose the prevalence of false positives from four of the five disorders screened by Panorama. The Campaign for Accountability complaint letter also alleged that the Company issued false and misleading statements about the accuracy of Panorama. The CfA website also highlights that Natera’s Chief Operating Officer sold approximately 10,800 shares of Natera stock valued at more than $800,000 in the weeks leading up to the publication, which may indicate he knew the story would hurt the Company’s share price in potential violation of insider trading laws.
Then on March 9, 2022, Hindenburg Research released a short report claiming multiple allegations. Most notably, the report stated, “Natera’s revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers.”
What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or [email protected].
About Johnson Fistel, LLP. Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in securities class action and derivative lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, Lead Securities Analyst
Telephone: (619) 814-4471
Email: [email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/116254
Source: Newsfile Corp.
Release ID: 194053
There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any security or any other product or service in this article. Moreover, nothing contained in this PR should be construed as a recommendation to buy, sell, or hold any investment or security, or to engage in any investment strategy or transaction. It is your responsibility to determine whether any investment, investment strategy, security, or related transaction is appropriate for you based on your investment objectives, financial circumstances, and risk tolerance. Consult your business advisor, attorney, or tax advisor regarding your specific business, legal, or tax situation.
